ROCKVILLE, Md. - (Business Wire) Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that the Company’s novel anti-cancer drug, Archexin™, has been selected as one of the Top 10 most promising oncology products in development that is available for strategic partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries. As a selected company, Rexahn has been invited to present data on Archexin at Windhover’s Therapeutic Area Partnerships conference on November 17-19, 2009, in Boston, MA.
The selection committee was led by Marc Wortman, Ph.D., contributing writer to Windhover’s In Vivo and Start Up, and a team from Campbell Alliance, a leading business development strategy consulting firm. Drawing on the analytic resources of these organizations, the group evaluated hundreds of compounds currently in development for the treatment of cancer prior to selecting Archexin to be among the top ten most attractive oncology products available for strategic partnering.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committee considered the most attractive oncology opportunities the industry has to offer," said Roger Longman, Managing Director of Windhover Information. "Winners have met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability.”
“The respective opinions of Windhover and Campbell Alliance are relied upon by the biomedical industry's top executives, consultants, bankers and investors to make the important strategic decisions. After careful analysis and consideration, we are delighted that these organizations have come to recognize Archexin as one of the Top 10 most promising oncology compounds in clinical development,” remarked Dr. Chang Ahn, Chairman and Chief Executive Officer of Rexahn. “Archexin has the potential to become an important therapeutic for the treatment of pancreatic cancer, which has a mortality rate of almost 100%. We look forward to 2010 when we expect preliminary human data from our ongoing Phase II trials.”
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. For more information please visit www.rexahn.com.
About Windhover
Windhover Information Inc (www.windhover.com), an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, the Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars.
Safe Harbor
This press release contains forward-looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn's lack of profitability, and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.
KCSA Strategic Communications
Investor Relations:
Jeffrey Goldberger / Yemi Rose
212-896-1249 / 212-896-1233
jgoldberger@kcsa.com / yrose@kcsa.com
or
Base Pair Communications
Industry and Press Relations:
Constantine Theodoropulos, 617-401-3116
Constantine@basepaircomm.com
